Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Beckham TH, et al. Among authors: diavolitsis vm. Int J Cancer. 2020 Jul 1;147(1):107-115. doi: 10.1002/ijc.32736. Epub 2019 Nov 11. Int J Cancer. 2020. PMID: 31609479 Free article.
Effect of adjuvant radiotherapy treatment center volume on overall survival.
Philips R, Martin D, Eskander A, Schord J, Brown N, Zhao S, Brock G, Kumar B, Carrau R, Ozer E, Agrawal A, Kang SY, Rocco JW, Schuller D, Ali S, Blakaj D, Bhatt A, Grecula J, Teknos T, Diavolitsis V, Old M. Philips R, et al. Oral Oncol. 2018 Mar;78:46-51. doi: 10.1016/j.oraloncology.2018.01.004. Epub 2018 Jan 20. Oral Oncol. 2018. PMID: 29496057 Free PMC article.
Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL, Walston S, Zamora P, Healy EH, Nolan N, Diavolitsis VM, Neki A, Rupert R, Savvides P, Agrawal A, Old M, Ozer E, Carrau R, Kang S, Rocco J, Teknos T, Grecula JC, Wobb J, Mitchell D, Blakaj D, Bhatt AD. Barney CL, et al. Among authors: diavolitsis vm. Oral Oncol. 2018 Apr;79:9-14. doi: 10.1016/j.oraloncology.2018.02.001. Epub 2018 Feb 12. Oral Oncol. 2018. PMID: 29598954
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, Kumar B, Kumar P, Pan Q, Palettas M, Wei L, Baiocchi R, Savvides P. Teknos TN, et al. Invest New Drugs. 2019 Aug;37(4):702-710. doi: 10.1007/s10637-018-0696-4. Epub 2018 Dec 19. Invest New Drugs. 2019. PMID: 30569244 Clinical Trial.
Primary vs nodal site PET/CT response as a prognostic marker in oropharyngeal squamous cell carcinoma treated with intensity-modulated radiation therapy.
Eckstein JM, Nolan N, Healy E, Wright CL, Jain A, Barney CL, Washington I, McElroy JP, Grecula JC, Wobb JL, Mitchell DL, Miller E, Gamez M, Blakaj D, Diavolitsis V, Bhatt A. Eckstein JM, et al. Head Neck. 2020 Sep;42(9):2405-2413. doi: 10.1002/hed.26242. Epub 2020 May 11. Head Neck. 2020. PMID: 32391626
Thyroid-optimized and thyroid-sparing radiotherapy in oral cavity and oropharyngeal carcinoma: A dosimetric study.
Wu AK, Damico NJ, Healy E, Kharouta MZ, Khandel G, Deshane A, Sipos J, Eckstein J, Zoller W, Ewing A, Ling S, Wobb J, Mitchell D, Grecula J, Jhawar S, Miller E, Gamez M, Diavolitsis V, Blakaj D, Bhatt AD. Wu AK, et al. Tech Innov Patient Support Radiat Oncol. 2021 Nov 1;20:28-34. doi: 10.1016/j.tipsro.2021.10.003. eCollection 2021 Dec. Tech Innov Patient Support Radiat Oncol. 2021. PMID: 34765751 Free PMC article.
16 results